Shingrix Shingles Vaccine: FDA Wants GSK To Monitor Inflammation Risk

GlaxoSmithKline's vaccine has 97.16% efficacy, surpassing Merck's Zostavax, but US advisory committee will weigh risks from inflammation which could cause ocular adverse effects and gout.